Gynecologic Cancers | Clinical

FDA Grants Priority Review to Cemiplimab for Recurrent/Metastatic Cervical Cancer

September 28, 2021

The FDA has accepted and granted priority review to the supplemental biologics license application for the PD-1 inhibitor cemiplimab-wlc for the treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.

Notable Activity in Recurrent/Metastatic Cervical Cancer Seen With Tisotumab Vedotin Plus Frontline Carboplatin and Second-/Third-Line Pembrolizumab

September 19, 2021

Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.

Perioperative Pembrolizumab Shows Activity in Advanced High-Grade Serous Carcinoma

August 19, 2021

In an interview with Targeted Oncology™, Isabelle Ray-Coquard, MD, PhD, discussed the NEOPEMBROV study in greater detail and the benefits of adding pembrolizumab to perioperative treatment for serous carcinoma deemed non-optimally resectable.